Close

Dr. Reddy’s introduces Desloratadine ODT in US

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Boehringer Ingelheim Integrates Owkin K Pro AI to Accelerate Drug Discovery

Boehringer Ingelheim has joined other pharmaceutical leaders in deploying Owkin's agentic AI scientist, K Pro, to analyze multimodal patient data in oncology and immunology R&D.

EMA Initiates Data Sharing Pilot for New Approach Methodologies

The European Medicines Agency has launched a voluntary framework for sharing data from non-animal testing methods to build regulatory confidence and refine drug development.

Antibody Performance Validation Improving Reproducibility in Pharmaceutical Research

The pharmaceutical industry currently faces a significant challenge regarding...
- Advertisement -

Dr. Reddy’s Laboratories has received the FDA approval and introduced Desloratadine orally disintegrating tablets (ODT) in 2.5mg and 5mg strengths in the US.

Desloratadine ODT is a generic equivalent to Clarinex Reditabs (desloratadine), which according to IMS Health data had total sales of $5.3m in the US for the twelve months ending November 2012.

The company makes Desloratadine ODT of 2.5mg and 5mg strengths available in unit dose packages of 30.

Clarinex Reditabs is indicated to fight allergy with the same strength of Clarinex but with the additional convenience of a rapid disintegration without water.

The prescription nonsedating, antihistamine was approved for the treatment of indoor and outdoor allergies and hives of unknown cause.

World Pharma Today brings together the global pharmaceutical industry — from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives — through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

Boehringer Ingelheim Integrates Owkin K Pro AI to Accelerate Drug Discovery

Boehringer Ingelheim has joined other pharmaceutical leaders in deploying Owkin's agentic AI scientist, K Pro, to analyze multimodal patient data in oncology and immunology R&D.

EMA Initiates Data Sharing Pilot for New Approach Methodologies

The European Medicines Agency has launched a voluntary framework for sharing data from non-animal testing methods to build regulatory confidence and refine drug development.

Antibody Performance Validation Improving Reproducibility in Pharmaceutical Research

The pharmaceutical industry currently faces a significant challenge regarding...

Novo Nordisk and AWS Enter Strategic AI Partnership to Accelerate Drug Discovery

Novo Nordisk has announced a strategic partnership with Amazon...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »